Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) as induction treatment in newly diagnosed Acute Myeloid Leukemia with TP53-mutantion

Fang Zheng, Xiaohui SUO, Jie Liu, Liyun Zhao, Guanchen Bai, Xingli Zhao, Yanliang Bai, Dongmei Wang, Yingchang Mi, Kaiqi Liu

Blood (2025) 146 (Supplement 1): 3395.

https://doi.org/10.1182/blood-2025-3395

Published: 2025

Journal Articles

Venetoclax combined with three-day multi-frequency decitabine, vincristine and dexamethasone (VDVD) as induction treatment for patients with de novo acute leukaemias of ambiguous lineage

Xingli Zhao, Xiaohui SUO, Guanchen Bai, Yanliang Bai, Fang Zheng, Jie Liu, Ling Li, Yingchang Mi, Kaiqi Liu

Blood (2025) 146 (Supplement 1): 3451.

https://doi.org/10.1182/blood-2025-3451

Published: 2025

Journal Articles

Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) VS venetoclax combined with azacitidine in elderly patients with Acute Myeloid Leukemia：a phase III, prospective, multicenter, randomized controlled trial

ZePing Zhou, Yaxian Tan, Xingli Zhao, Xiaohui SUO, Guanchen Bai, Yanliang Bai, Yunya Luo, Mei Lan, Xinxiao Lu, Linyu Yuan, Congcong Zhang, Yinling Li, Sifeng Gao, Jilei Zhang, Heng Li, Hongling Peng, Pengxiang Guo, Yingchang Mi, Kaiqi Liu

Blood (2025) 146 (Supplement 1): 3450.

https://doi.org/10.1182/blood-2025-3450

Published: 2025

Journal Articles

7-day venetoclax combined with intensive chemotherapy as induction treatment in newly diagnosed Acute Myeloid Leukemia with splicing factor gene mutations

Congcong Zhang, Xiaohui SUO, Xingli Zhao, Guanchen Bai, Yanliang Bai, Hongling Peng, Fang Zheng, Dongmei Wang, Liyun Zhao, ZePing Zhou, Yingchang Mi, Kaiqi Liu

Blood (2025) 146 (Supplement 1): 1618.

https://doi.org/10.1182/blood-2025-1618

Published: 2025

Journal Articles

7-day venetoclax combined with intensive chemotherapy as induction treatment in high-risk newly diagnosed Acute Myeloid Leukemia

Xiaohan Zhang, Xiaohui SUO, Guanchen Bai, Xingli Zhao, Yanliang Bai, Hongling Peng, Fang Zheng, Dongmei Wang, Liyun Zhao, ZePing Zhou, Yingchang Mi, Kaiqi Liu

Blood (2025) 146 (Supplement 1): 1617.

https://doi.org/10.1182/blood-2025-1617

Published: 2025

Journal Articles

A real-world study on first-line early switch to kpd regimen in the treatment of multiple myeloma patients with suboptimal induction efficacy or intolerance

xu Ji, Yanliang Bai, jiangxue Hou, tao Liu, ping Wang, sun Wu, weiling Qin, chao Li, junjie Yin, genjie Wang, zheng Xu, shuhao mei, guochao Ji, Wenyi Lu, Baijun Fang, quande Lin

Blood (2025) 146 (Supplement 1): 7548.

https://doi.org/10.1182/blood-2025-7548

Published: 2025

Journal Articles

Updated real-world outcomes with brentuximab vedotin in lymphoma patients: A multicenter, retrospective study from China

Honghan Qiao, Xingchen Liu, Huijie Nan, Mingzhi Zhang, Yanliang Bai, Keshu Zhou, Xudong Zhang

Blood (2025) 146 (Supplement 1): 7206.

https://doi.org/10.1182/blood-2025-7206

Published: 2025

Journal Articles

Venetoclax combined with three-day multi-frequency Decitabine (DEC3-VEN) in the treatment of adult patients with de novo Acute Myeloid Leukemia：updated results of a phase II trial

ZePing Zhou, Yaxian Tan, Xingli Zhao, Xiaohui SUO, Guanchen Bai, Yanliang Bai, Yunya Luo, Mei Lan, Xinxiao Lu, Linyu Yuan, Congcong Zhang, Yinling Li, Sifeng Gao, Jilei Zhang, Hongling Peng, Pengxiang Guo, Yingchang Mi, Kaiqi Liu

Blood (2025) 146 (Supplement 1): 1675.

https://doi.org/10.1182/blood-2025-1675

Published: 2025

Journal Articles

Venetoclax Combined with Three-Day Multi-Frequency Decitabine and Homoharringtonine (DEC3-VEN-HHT) As Induction Therapy in Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia

Lei Ju, Xingli Zhao, Xiaohui Suo, ZePing Zhou, Yanliang Bai, Yunya Luo, Sifeng Gao, Xinxiao Lu, Linyu Yuan, Congcong Zhang, Yinling Li, Yaxian Tan, Guanchen Bai, Hongling Peng, Pengxiang Guo, Yingchang Mi, Kaiqi Liu

Blood (2024) 144 (Supplement 1): 1505.

https://doi.org/10.1182/blood-2024-202971

Published: 2024

Journal Articles

7-Day Venetoclax Combined with Intensive Chemotherapy As Induction Treatment in Newly Diagnosed Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 2885.

https://doi.org/10.1182/blood-2024-198844

Published: 2024

Journal Articles

Venetoclax Combined with Intensive Chemotherapy As an Induction Chemotherapy in Newly Diagnosed FLT3-ITD Positive AML

Blood (2024) 144 (Supplement 1): 1485.

https://doi.org/10.1182/blood-2024-203422

Published: 2024

Journal Articles

Homoharringtonine Combining with Azacitidine and Venetoclax (HAV) As First-Line Induction Therapy for Newly Diagnosed Adult Acute Myeloid Leukemia Patients

Wenyi Lu, Xiangli Chen, Yuzhu Zang, Zunmin Zhu, Wenhui Zhang, Yanliang Bai, Yuqing Chen, Li Jiang, Yanyan Xing, Yuanbo Liu, Jie Shi, Zhenxing Gao

Blood (2024) 144 (Supplement 1): 6037.

https://doi.org/10.1182/blood-2024-203408

Published: 2024

Journal Articles

Venetoclax Combined with Three-Day Multi-Frequency Decitabine (DEC3-VEN) VS Venetoclax Combined with Azacitidine in Elderly Patients with Acute Myeloid Leukemia：a Phase III, Prospective, Multicenter, Randomized Controlled Trial

ZePing Zhou, Yaxian Tan, Xingli Zhao, Xiaohui Suo, Guanchen Bai, Yanliang Bai, Yunya Luo, Xinxiao Lu, Linyu Yuan, Congcong Zhang, Yinling Li, Sifeng Gao, Jilei Zhang, Hongling Peng, Pengxiang Guo, Yingchang Mi, Kaiqi Liu

Blood (2024) 144 (Supplement 1): 6035.

https://doi.org/10.1182/blood-2024-202495

Published: 2024

Journal Articles

Venetoclax Combined with Three-Day Multi-Frequency Decitabine (DEC3-VEN) in the Treatment of Adult Patients with De Novo Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 4279.

https://doi.org/10.1182/blood-2024-202430

Published: 2024

Journal Articles

A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

Blood (2024) 144 (18): 1951–1961.

https://doi.org/10.1182/blood.2024024761

Published: 2024

Includes: Supplemental data

Journal Articles

Low Erythropoietin to Albumin Ratio in the Serum Predicts Less Reversibility of Renal Impairment with Poorer Prognosis in Multiple Myeloma

Kai Sun, Ying Liu, Yanliang Bai, Haoyan Wang, Mengzhen Wang, Yuan Chen, Li Bao

Blood (2023) 142 (Supplement 1): 6681.

https://doi.org/10.1182/blood-2023-182670

Published: 2023

Journal Articles

H3K36 Trimethylation Mediated By SETD2 Regulates Cell Proliferation and Cell Cycle By Modulating BCMA-JNK and c-Myc Pathways in Multiple Myeloma

Pan Zhou, Mengyu Xiao, Yanliang Bai, Huixia Cao, Weiping Yuan, Fengmin Shao, Kai Sun

Blood (2021) 138 (Supplement 1): 2200.

https://doi.org/10.1182/blood-2021-145120

Published: 2021

Journal Articles

Allogeneic CAR-T Cell Therapy for Treatment of Relapse after Allo-HSCT in Patients with Refractory CML Lymphoid Blast Crisis: Significance of HLA Matched Donor/Patient Pair in the Safety/Efficacy of CAR-T Cell Therapy

Kai Sun, MD, Xuejun Zhang, MD, Zhen Wang, MD, Yuqing Chen, MD, Lei Zhang, MD, Wei Cheng, MD, Mingyue Shi, MD, Lei Huo, MD, Yanliang Bai, MD, Xiaona Niu, MD, Honggang Guo, MD, Jing Yang, MD, Chunrong Tong, MD, AlexH Chang, MD, PhD

Blood (2018) 132 (Supplement 1): 4275.

https://doi.org/10.1182/blood-2018-99-115768

Published: 2018

Journal Articles

The Value of FDP/FIB and D-Dimer/FIB Ratios: Predicting High-Risk APL Related Thrombosis

Yanliang Bai, MD, Mingyue Shi, MD, Wanjun Zhang, MD, Xiawan Yang, MD, Hafiz Abdul Waqas Ahmed, MD, Lei Huo, MD, Yuqing Chen, MD, Xiaona Niu, MD, Honggang Guo, MD, Fangfang Xu, MD, PhD, Jing Yang, MD, Yuzhu Zang, MD, Shuangyin Han, MD, PhD, Kai Sun, MD

Blood (2018) 132 (Supplement 1): 5010.

https://doi.org/10.1182/blood-2018-99-113453

Published: 2018

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) as induction treatment in newly diagnosed Acute Myeloid Leukemia with TP53-mutantion

Venetoclax combined with three-day multi-frequency decitabine, vincristine and dexamethasone (VDVD) as induction treatment for patients with de novo acute leukaemias of ambiguous lineage

Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) VS venetoclax combined with azacitidine in elderly patients with Acute Myeloid Leukemia：a phase III, prospective, multicenter, randomized controlled trial

7-day venetoclax combined with intensive chemotherapy as induction treatment in newly diagnosed Acute Myeloid Leukemia with splicing factor gene mutations

7-day venetoclax combined with intensive chemotherapy as induction treatment in high-risk newly diagnosed Acute Myeloid Leukemia

A real-world study on first-line early switch to kpd regimen in the treatment of multiple myeloma patients with suboptimal induction efficacy or intolerance

Updated real-world outcomes with brentuximab vedotin in lymphoma patients: A multicenter, retrospective study from China

Venetoclax combined with three-day multi-frequency Decitabine (DEC3-VEN) in the treatment of adult patients with de novo Acute Myeloid Leukemia：updated results of a phase II trial

Venetoclax Combined with Three-Day Multi-Frequency Decitabine and Homoharringtonine (DEC3-VEN-HHT) As Induction Therapy in Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia

7-Day Venetoclax Combined with Intensive Chemotherapy As Induction Treatment in Newly Diagnosed Acute Myeloid Leukemia

Venetoclax Combined with Intensive Chemotherapy As an Induction Chemotherapy in Newly Diagnosed FLT3-ITD Positive AML

Homoharringtonine Combining with Azacitidine and Venetoclax (HAV) As First-Line Induction Therapy for Newly Diagnosed Adult Acute Myeloid Leukemia Patients

Venetoclax Combined with Three-Day Multi-Frequency Decitabine (DEC3-VEN) VS Venetoclax Combined with Azacitidine in Elderly Patients with Acute Myeloid Leukemia：a Phase III, Prospective, Multicenter, Randomized Controlled Trial

Venetoclax Combined with Three-Day Multi-Frequency Decitabine (DEC3-VEN) in the Treatment of Adult Patients with De Novo Acute Myeloid Leukemia

A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

Low Erythropoietin to Albumin Ratio in the Serum Predicts Less Reversibility of Renal Impairment with Poorer Prognosis in Multiple Myeloma

H3K36 Trimethylation Mediated By SETD2 Regulates Cell Proliferation and Cell Cycle By Modulating BCMA-JNK and c-Myc Pathways in Multiple Myeloma

Allogeneic CAR-T Cell Therapy for Treatment of Relapse after Allo-HSCT in Patients with Refractory CML Lymphoid Blast Crisis: Significance of HLA Matched Donor/Patient Pair in the Safety/Efficacy of CAR-T Cell Therapy

The Value of FDP/FIB and D-Dimer/FIB Ratios: Predicting High-Risk APL Related Thrombosis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only